Advanced search

Online first
Review paper
Published online: 2024-05-20

open access

View PDF Download PDF file
Page views 155
Article views/downloads 85
Get Citation

Connect on Social Media

Connect on Social Media

The management of oral cancer – current standards and future perspectives. Review of the literature

Natalia Amrogowicz1, Tomasz Rutkowski2
DOI: 10.5603/njo.99156

Abstract

Oral cancer (OC) is one of the most common cancers of the head and neck region, with approximately 1,950 new cases reported in Poland in 2019. The main factors contributing to the development of OC are cigarette smoking and excessive alcohol consumption. Squamous cell carcinoma accounts for more than 90% of all OCs. In patients with OC surgery is the treatment of choice, but there is a high number of patients who require complementary treatment – radiotherapy or radiochemotherapy. The treatment of these tumours should be comprehensive and multidisciplinary. Due to suboptimal treatment outcomes in this patient group, numerous clinical trials are being conducted to search for new, more effective treatments. The aim of this study was to review the literature on current and new methods of diagnosis and treatment of OC and to analyse the clinical trials currently available for OC patients in Poland. Despite the use of modern drugs, only modest progress has been made in terms of treatment efficacy.

Keywords: oral cancer treatmentclinical trials

Article available in PDF format

View PDF Download PDF file

References

  1. WHO, Cancer Today, Raport 2020. https://gco.iarc.fr/.
  2. Krajowy Rejestr Nowotworów. https://onkologia.org.pl/pl/raporty.
  3. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988; 48(11): 3282–3287.
    PubMed
  4. International Agency on Research for Cancer. Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines. Monographs Vol. 89. IARC, Lyon 2007.
  5. Warnakulasuriya S, Sutherland G, Scully C. Tobacco, oral cancer, and treatment of dependence. Oral Oncol. 2005; 41(3): 244–260.
    CrossRefPubMed
  6. Scully C. Oral cancer aethiopathogenesis; past, present and future aspects. Med Oral Patol Oral Cir Bucal. 2011; 16(3): e306–e311.
    CrossRefPubMed
  7. Wen CP, Tsai MK, Chung WS, et al. Cancer risks from betel quid chewing beyond oral cancer: a multiple-site carcinogen when acting with smoking. Cancer Causes Control. 2010; 21(9): 1427–1435.
    CrossRefPubMed
  8. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007; 356(19): 1944–1956.
    CrossRefPubMed
  9. Herrero R, Castellsagué X, Pawlita M, et al. IARC Multicenter Oral Cancer Study Group. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003; 95(23): 1772–1783.
    CrossRefPubMed
  10. Biesaga B, Smolarczyk R, Mucha-Małecka A, et al. Prognostic Significance of STING Immunoexpression in Relation to HPV16 Infection in Patients with Squamous Cell Carcinomas of Oral Cavity and Oropharynx. Biomedicines. 2022; 10(10).
    CrossRefPubMed
  11. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 91(6): 622–635.
    CrossRefPubMed
  12. Shillitoe EJ. The role of viruses in squamous cell carcinoma of the oropharyngeal mucosa. Oral Oncol. 2009; 45(4-5): 351–355.
    CrossRefPubMed
  13. Sulkowska U, Mańczuk M, Przewoźniak K, et al. Estimating of the number of cancer cases attributed to HPV infections for Poland in 2015. Nowotwory. Journal of Oncology. 2018; 68(4): 173–175.
    CrossRef
  14. Popović B, Jekić B, Novaković I, et al. Cancer genes alterations and HPV infection in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2010; 39(9): 909–915.
    CrossRefPubMed
  15. Eglin RP, Scully C, Lehner T, et al. Detection of RNA complementary to herpes simplex virus in human oral squamous cell carcinoma. Lancet. 1983; 2(8353): 766–768.
    CrossRefPubMed
  16. Shillitoe EJ. The role of viruses in squamous cell carcinoma of the oropharyngeal mucosa. Oral Oncol. 2009; 45(4-5): 351–355.
    CrossRefPubMed
  17. Zheng Y, Xia Pu, Zheng HC, et al. The screening of viral risk factors in tongue and pharyngolaryngeal squamous carcinoma. Anticancer Res. 2010; 30(4): 1233–1238.
    PubMed
  18. Bagan JV, Jiménez Y, Murillo J, et al. Epstein-Barr virus in oral proliferative verrucous leukoplakia and squamous cell carcinoma: A preliminary study. Med Oral Patol Oral Cir Bucal. 2008; 13(2): E110–E113.
    PubMed
  19. Jalouli J, Ibrahim SO, Mehrotra R, et al. Prevalence of viral (HPV, EBV, HSV) infections in oral submucous fibrosis and oral cancer from India. Acta Otolaryngol. 2010; 130(11): 1306–1311.
    CrossRefPubMed
  20. Laborde RR, Novakova V, Olsen KD, et al. Expression profiles of viral responsive genes in oral and oropharyngeal cancers. Eur J Cancer. 2010; 46(6): 1153–1158.
    CrossRefPubMed
  21. Yen CY, Lu MC, Tzeng CC, et al. Detection of EBV infection and gene expression in oral cancer from patients in Taiwan by microarray analysis. J Biomed Biotechnol. 2009; 2009: 904589.
    CrossRefPubMed
  22. Kis A, Fehér E, Gáll T, et al. Epstein-Barr virus prevalence in oral squamous cell cancer and in potentially malignant oral disorders in an eastern Hungarian population. Eur J Oral Sci. 2009; 117(5): 536–540.
    CrossRefPubMed
  23. Fitzpatrick SG, Katz J. The association between periodontal disease and cancer: a review of the literature. J Dent. 2010; 38(2): 83–95.
    CrossRefPubMed
  24. Yamazaki H, Inoue T, Yoshida K, et al. Assessment of influence of smoking, drinking, leukoplakia and dental irritation on local control of early oral tongue carcinoma treated with brachytherapy: age and dental factors are potential prognostic factors. Tumori. 2009; 95(4): 461–466.
    CrossRefPubMed
  25. Freedman ND, Park Y, Subar AF, et al. Fruit and vegetable intake and head and neck cancer risk in a large United States prospective cohort study. Int J Cancer. 2008; 122(10): 2330–2336.
    CrossRefPubMed
  26. Bosetti C, Gallus S, Trichopoulou A, et al. Influence of the Mediterranean diet on the risk of cancers of the upper aerodigestive tract. Cancer Epidemiol Biomarkers Prev. 2003; 12(10): 1091–1094.
    PubMed
  27. Sakthivel P, Raveendran S, Panda S, et al. Oral potential malignant disorders - A long list not to be forgotten. Oral Oncol. 2021; 116: 105244.
    CrossRefPubMed
  28. Prime SS, Thakker NS, Pring M, et al. A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma. Oral Oncol. 2001; 37(1): 1–16.
    CrossRefPubMed
  29. Irani S. Pre-Cancerous Lesions in the Oral and Maxillofacial Region: A Literature Review with Special Focus on Etiopathogenesis. Iran J Pathol. 2016; 11(4): 303–322.
    PubMed
  30. Khan MM, Frustino J, Villa A, et al. Total RNA sequencing reveals gene expression and microbial alterations shared by oral pre-malignant lesions and cancer. Hum Genomics. 2023; 17(1): 72.
    CrossRefPubMed
  31. Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015; 8(9): 11884–11894.
    PubMed
  32. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009; 45(4-5): 309–316.
    CrossRefPubMed
  33. Wierzbicka M. Nowotwory jamy ustnej. In: Szyfter W. ed. Nowotwory w otolaryngologii wyd. II. Termedia, Poznań 2015: 177–211.
  34. Ettinger KS, Ganry L, Fernandes RP. Oral Cavity Cancer. Oral Maxillofac Surg Clin North Am. 2019; 31(1): 13–29.
    CrossRefPubMed
  35. Shah JP, Gil Z. Current concepts in management of oral cancer--surgery. Oral Oncol. 2009; 45(4-5): 394–401.
    CrossRefPubMed
  36. Lo WL, Kao SY, Chi LY, et al. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg. 2003; 61(7): 751–758.
    CrossRefPubMed
  37. Byers RM, El-Naggar AK, Lee YY, et al. Can we detect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue? Head Neck. 1998; 20(2): 138–144, doi: 10.1002/(sici)1097-0347(199803)20:2<138::aid-hed7>3.0.co;2-3.
    PubMed
  38. Shah J, Candela F, Poddar A. The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer. 1990; 66(1): 109–113, doi: 10.1002/1097-0142(19900701)66:1<109::aid-cncr2820660120>3.0.co;2-a.
    PubMed
  39. Massey C, Dharmarajan A, Bannuru RR, et al. Management of N0 neck in early oral squamous cell carcinoma: A systematic review and meta-analysis. Laryngoscope. 2019; 129(8): E284–E298.
    CrossRefPubMed
  40. Haseeb AA, Rahim AUr, Iqbal S, et al. The frequency of occult cervical metastasis in oral squamous cell carcinoma patients - A cross sectional study. J Pak Med Assoc. 2022; 72(1): 66–70.
    CrossRefPubMed
  41. Byers RM, Weber RS, Andrews T, et al. Frequency and therapeutic implications of "skip metastases" in the neck from squamous carcinoma of the oral tongue. Head Neck. 1997; 19(1): 14–19, doi: 10.1002/(sici)1097-0347(199701)19:1<14::aid-hed3>3.0.co;2-y.
    PubMed
  42. Koyfman SA, Ismaila N, Crook D, et al. Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline. J Clin Oncol. 2019; 37(20): 1753–1774.
    CrossRefPubMed
  43. Paleri V, Urbano TG, Mehanna H, et al. Management of neck metastases in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130(S2): S161–S169.
    CrossRefPubMed
  44. Fridman E, Na'ara S, Agarwal J, et al. International Consortium for Outcome Research in Head and Neck Cancer. The role of adjuvant treatment in early-stage oral cavity squamous cell carcinoma: An international collaborative study. Cancer. 2018; 124(14): 2948–2955.
    CrossRefPubMed
  45. Chen WC, Lai CH, Fang CC, et al. Identification of High-Risk Subgroups of Patients With Oral Cavity Cancer in Need of Postoperative Adjuvant Radiotherapy or Chemo-Radiotherapy. Medicine (Baltimore). 2016; 95(22): e3770.
    CrossRefPubMed
  46. Amin MB, Edge S, Greene F, et al. AJCC cancer staging manual. Eight edition. Springer 2017.
  47. Fukano H, Matsuura H, Hasegawa Y, et al. Depth of invasion as a predictive factor for cervical lymph node metastasis in tongue carcinoma. Head Neck. 1997; 19(3): 205–210, doi: 10.1002/(sici)1097-0347(199705)19:3<205::aid-hed7>3.0.co;2-6.
    PubMed
  48. Bànkfalvi A, Piffkò J. Prognostic and predictive factors in oral cancer: the role of the invasive tumour front. J Oral Pathol Med. 2000; 29(7): 291–298.
    CrossRefPubMed
  49. Yamauchi M, Ishida T, Minesaki A, et al. WPOI-4/5 Correlates With Lymph Node Recurrence and Poor Prognosis in Early-stage Tongue Squamous Cell Carcinoma. Cancer Diagn Progn. 2023; 3(4): 457–462.
    CrossRefPubMed
  50. Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol. 2005; 29(2): 167–178.
    CrossRefPubMed
  51. Boxberg M, Bollwein C, Jöhrens K, et al. Novel prognostic histopathological grading system in oral squamous cell carcinoma based on tumour budding and cell nest size shows high interobserver and intraobserver concordance. J Clin Pathol. 2019; 72(4): 285–294.
    CrossRefPubMed
  52. Ragin CCR, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007; 121(8): 1813–1820.
    CrossRefPubMed
  53. Miranda-Galvis M, Rumayor Piña A, Sales de Sá R, et al. PD-L1 expression patterns in oral cancer as an integrated approach for further prognostic classification. Oral Dis. 2021; 27(7): 1699–1710.
    CrossRefPubMed
  54. Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017; 35(14): 1542–1549.
    CrossRefPubMed
  55. Cramer JD, Burtness B, Ferris RL. Immunotherapy for head and neck cancer: Recent advances and future directions. Oral Oncol. 2019; 99: 104460.
    CrossRefPubMed
  56. Snietura M, Jaworska M, Mlynarczyk-Liszka J, et al. PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck. PLoS One. 2012; 7(3): e33396.
    CrossRefPubMed
  57. Strzelczyk JK, Krakowczyk Ł, Gołąbek K, et al. Expression profiles of selected genes in tumors and matched surgical margins in oral cavity cancer: Do we have to pay attention to the molecular analysis of the surgical margins? Adv Clin Exp Med. 2018; 27(6): 833–840.
    CrossRefPubMed
  58. Lei Yu, Xie Y, Tan YS, et al. Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer. Oral Oncol. 2016; 61: 159–165.
    CrossRefPubMed
  59. Maiti GP, Mondal P, Mukherjee N, et al. Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes. PLoS One. 2013; 8(5): e63440.
    CrossRefPubMed
  60. Schena M, Guarrera S, Buffoni L, et al. DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients. DNA Repair (Amst). 2012; 11(4): 374–380.
    CrossRefPubMed
  61. Wróbel-Roztropiński A, Zielińska-Kaźmierska B, Roztropiński H, et al. Expression of matrix metalloproteinases (MMPs) and their inhibitor (TIMP) genes on mRNA and protein levels in oral squamous cell carcinoma. Nowotwory. Journal of Oncology. 2021; 71(1): 1–8.
    CrossRef
  62. Peters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993; 26(1): 3–11.
    CrossRefPubMed
  63. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001; 51(3): 571–578.
    CrossRefPubMed
  64. Bernier J, Domenge C, Ozsahin M, et al. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350(19): 1945–1952.
    CrossRefPubMed
  65. Cooper JS, Pajak TF, Forastiere AA, et al. Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350(19): 1937–1944.
    CrossRefPubMed
  66. Pfister DG, Spencer S, Adkins D, et al. Head and Neck Cancers, Version 2.2023. NCCN Clinical Practice Guidelines in Oncology .
  67. Sumioka S, Sawai NY, Kishino M, et al. Risk factors for distant metastasis in squamous cell carcinoma of the oral cavity. J Oral Maxillofac Surg. 2013; 71(7): 1291–1297.
    CrossRefPubMed
  68. Rosenthal DI, Mohamed ASR, Garden AS, et al. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2017; 98(5): 1002–1011.
    CrossRefPubMed
  69. Langendijk JA, de Jong MA, Leemans CR, et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time. Int J Radiat Oncol Biol Phys. 2003; 57(3): 693–700.
    CrossRefPubMed
  70. Rosenthal DI, Liu Li, Lee JH, et al. Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck. 2002; 24(2): 115–126.
    CrossRefPubMed
  71. Mucha-Małecka A, Składowski K, Lange D. Histopathological factors influencing results of combined treatment in patients with laryngeal cancer. Pol J Pathol. 2015; 66(3): 260–268.
    CrossRefPubMed
  72. Snyderman NL, Johnson JT, Schramm VL, et al. Extracapsular spread of carcinoma in cervical lymph nodes. Impact upon survival in patients with carcinoma of the supraglottic larynx. Cancer. 1985; 56(7): 1597–1599, doi: 10.1002/1097-0142(19851001)56:7<1597::aid-cncr2820560722>3.0.co;2-5.
    PubMed
  73. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996; 36(5): 999–1004.
    CrossRefPubMed
  74. Skóra T, Nowak-Sadzikowska J, Mucha-Małecka A, et al. Postoperative irradiation in patients with pT3-4N0 laryngeal cancer: results and prognostic factors. Eur Arch Otorhinolaryngol. 2015; 272(3): 673–679.
    CrossRefPubMed
  75. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27(10): 843–850.
    CrossRefPubMed
  76. Rutkowski T, Wygoda A, Hutnik M, et al. Intraoperative radiotherapy (IORT) with low-energy photons as a boost in patients with early-stage oral cancer with the indications for postoperative radiotherapy : treatment feasibility and preliminary results. Strahlenther Onkol. 2010; 186(9): 496–501.
    CrossRefPubMed
  77. Chamoli A, Gosavi AS, Shirwadkar UP, et al. Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics. Oral Oncol. 2021; 121: 105451.
    CrossRefPubMed
  78. de Oliveira TB, Marta GN, de Castro Junior G, et al. Induction Chemotherapy for Advanced Oral Cavity Cancer. Curr Oncol Rep. 2021; 23(11): 129.
    CrossRefPubMed
  79. Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol. 2003; 21(2): 327–333.
    CrossRefPubMed
  80. Marta GN, Riera R, Bossi P, et al. Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. Eur J Cancer. 2015; 51(17): 2596–2603.
    CrossRefPubMed
  81. https://clinicaltrials.gov/study/NCT03576417.
  82. https://classic.clinicaltrials.gov/ct2/show/NCT04459715?term=Debio+1143-SCCHN-301&draw=2&rank=1.
  83. Tam S, Araslanova R, Low THH, et al. Estimating Survival After Salvage Surgery for Recurrent Oral Cavity Cancer. JAMA Otolaryngol Head Neck Surg. 2017; 143(7): 685–690.
    CrossRefPubMed
  84. Tian Z, Wang S, Xia R, et al. Salvage Surgery for Recurrent Tongue Cancer With Contralateral Neck Metastasis. J Oral Maxillofac Surg. 2021; 79(2): 490–500.
    CrossRefPubMed
  85. Vargo JA, Ward MC, Caudell JJ, et al. A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2018; 100(3): 595–605.
    CrossRefPubMed
  86. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008; 30(3): 281–288.
    CrossRefPubMed
  87. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007; 25(30): 4800–4805.
    CrossRefPubMed
  88. Matoscevic K, Graf N, Pezier TF, et al. Success of salvage treatment: a critical appraisal of salvage rates for different subsites of HNSCC. Otolaryngol Head Neck Surg. 2014; 151(3): 454–461.
    CrossRefPubMed
  89. Gibson MK, Li Yi, Murphy B, et al. Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23(15): 3562–3567.
    CrossRefPubMed
  90. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006; 24(17): 2644–2652.
    CrossRefPubMed
  91. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11): 1116–1127.
    CrossRefPubMed
  92. Burtness B, Rischin D, Greil R, et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol. 2022; 40(21): 2321–2332.
    CrossRefPubMed
  93. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19): 1856–1867.
    CrossRefPubMed
  94. https://clinicaltrials.gov/study/NCT04199104.
  95. https://clinicaltrials.gov/study/NCT04128696.
  96. https://clinicaltrials.gov/study/NCT04534205.
  97. Palma DA, Olson RA, Harrow S, et al. Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol Biol Phys. 2018; 2013: S3–S4.
  98. Sun XuS, Michel C, Babin E, et al. Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC. Future Oncol. 2018; 14(9): 877–889.
    CrossRefPubMed
  99. Mohanti BK, Umapathy H, Bahadur S, et al. Short course palliative radiotherapy of 20 Gy in 5 fractions for advanced and incurable head and neck cancer: AIIMS study. Radiother Oncol. 2004; 71(3): 275–280.
    CrossRefPubMed
  100. Fortin B, Khaouam N, Filion E, et al. Paliative radiation therapy for advanced head and neck carcinomas: a phase 2 study. Int J Radiat Oncol Biol Phys. 2016; 95(2): 647–653.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice